Target intelligence / Profile preview

Long intergenic non-protein coding RNA 1373 (CASC22)

Target
CASC22
Molecular classification
Non-coding RNA, Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA)
01

Overview

CASC22 (Cancer susceptibility 22), also referenced as LINC01373, is a long intergenic non-coding RNA (lincRNA) not overlapping any protein-coding gene. LincRNAs are defined by being longer than 200 nucleotides, frequently regulating chromatin structure, gene expression, and sometimes possessing tissue- or disease-specific functions. While many lincRNAs have established roles in cancer, development, and cell cycle regulation, the specific biological or disease-related function of CASC22 remains uncharacterized in the literature currently available; its designation as "cancer susceptibility" is based on systematic annotation rather than experimental mechanism. CASC22 is transcribed but does not code for a protein and is believed to function primarily through RNA-based modification of gene regulatory networks, consistent with lincRNAs as a group.

Other names
Cancer susceptibility 22CASC22TCONS_00024290LincRNA-ENST00000515084LINC01373Cancer susceptibility candidate 22 (non-protein coding)Long intergenic non-protein coding RNA 1373LOC107983961
02

Biological functions

Chromatin remodelingTranscriptional regulationRegulation of neighboring gene expressionRNA stabilizationPotential enhancer-associated activityRegulation of genome architectureOther (most reported functions are general to the lincRNA family; specific functions of CASC22 remain uncharacterized)
03

Disease associations

Cancer (putative association suggested by name and lincRNA class involvement in cancer, but no direct experimental evidence for CASC22’s disease mechanism in current results)Other (potential; the class participates in varied disease contexts, but CASC22-specific roles are undefined)

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 1373 (CASC22).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 1373 (CASC22).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call